Alison Bateman-House

Alison Bateman-House is a Part-time Professor of Practice in Law at the University of Arizona's Arizona Law and an Assistant Professor in the Division of Medical Ethics at NYU Grossman School of Medicine. She co-chairs the Working Group on Compassionate Use and Preapproval Access (CUPA) and chairs the NYU/Janssen Compassionate Use Advisory Committees (CompACs) for Infectious Disease and NeuroPsychology, focusing on ethical issues in access to investigational medicines and human subjects research.

Her educational background includes:

• PhD
• MPH
• MA

Dr. Bateman-House's research centers on bioethics, particularly the ethical, legal, and regulatory challenges surrounding compassionate use, expanded access pathways, and gene therapy development. She examines patient-centered approaches in rare disease trials, pediatric considerations, and policy implications at the intersection of law and medicine, with emphasis on equity and scientific integrity.

Her recent publications (2022-2025) reveal a dominant focus on gene therapy ethics, N-of-1 therapeutic development, and compassionate use frameworks. Key trends include analyzing patient lived experiences in neurological gene trials, clinician perspectives on Duchenne Muscular Dystrophy treatments, and sustainable models for non-commercialized cell therapies, highlighting persistent gaps in regulatory science and access equity.

No scientific awards were mentioned in the provided text.

Information about student advising and research grants was not provided in the text, though her CompAC leadership implies active mentorship in ethics review processes.

She leads the Working Group on Compassionate Use and Preapproval Access (CUPA) and chairs the NYU/Janssen Compassionate Use Advisory Committees (CompACs), which guide ethical allocation decisions for investigational drugs through multidisciplinary collaboration with patient advocates, clinicians, and industry representatives.